Related Experiment Video
Updated: Jul 2, 2025

Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans
Published on: October 5, 2020
SERPINE2 promotes liver cancer metastasis by inhibiting c-Cbl-mediated EGFR ubiquitination and degradation
Shiyu Zhang1,2,3,4, Xing Jia1,2,3,4, Haojiang Dai1,2,3,4
1Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, P. R. China.
Serpin family E member 2 (SERPINE2) promotes liver cancer metastasis by stabilizing epidermal growth factor receptor (EGFR). Inhibiting the SERPINE2-EGFR pathway may offer a new liver cancer treatment strategy.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Liver cancer presents high morbidity and mortality rates.
- Serpin family E member 2 (SERPINE2) is implicated in the metastasis of various cancers.
- Understanding SERPINE2's role in liver cancer metastasis is crucial for developing effective treatments.
Purpose of the Study:
- To investigate the mechanism by which SERPINE2 contributes to liver cancer metastasis.
- To identify SERPINE2 as a potential therapeutic target in liver cancer.
Main Methods:
- Utilized The Cancer Genome Atlas (TCGA) database for DNA methylation and transcriptome data analysis.
- Performed RNA sequencing, cytokine assays, immunoprecipitation (IP), mass spectrometry (MS), protein stability, and ubiquitination assays.
- Employed patient-derived xenografts and tumor organoid models to assess SERPINE2's role in sorafenib treatment.
Main Results:
- SERPINE2, regulated by DNA methylation, was identified as a tumor promoter in liver cancer, with higher expression correlating with poor prognosis.
- SERPINE2 enhanced liver cancer metastasis by promoting cell pseudopodia formation, adhesion, cancer-associated fibroblast activation, extracellular matrix remodeling, and angiogenesis.
- SERPINE2 stabilized epidermal growth factor receptor (EGFR) by inhibiting its ubiquitination via competition with c-Cbl, thereby activating downstream signaling pathways.
- SERPINE2 knockdown enhanced the efficacy of sorafenib and lenvatinib in preclinical models by downregulating EGFR.
Conclusions:
- SERPINE2 promotes liver cancer metastasis by stabilizing EGFR through inhibition of c-Cbl-mediated ubiquitination.
- Targeting the SERPINE2-EGFR axis presents a promising therapeutic strategy for liver cancer.
Related Concept Videos
Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Mitogens and the Cell Cycle
Hedgehog Signaling Pathway
PI3K/mTOR/AKT Signaling Pathway
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...

